Without naming sources or hard data to back up my
Without naming sources or hard data to back up my statements, I am currently more confident in the success of IPIX than I have been since last Spring when we seemed to start missing all our expectations as to news, deals, trial results, etc.
The start of my increasing confidence was the recent spate of PRs that seemed to be a pattern established by our potential partner as to what needed to be proven prior to their acceptance of a deal and to date we seem to have passed all requirements with flying colors.
Then came some correspondence with various people that I highly respect who have made me believe stronger than ever that Leo is being courted by BPs rather than chasing after one to give us any kind of deal.
The final link in the chain is that OM is now ready for P3 in having the sachets ready to go, IBD is oh so close to having the pill developed and that is IMO the key to the overall exploitation of the total value of Brilacidin (and yes, I do believe it will be the monster most of us have always expected, or at least dreamed, that it would become) and that Kevetrin is currently wearing its Chinese costume (that of a sleeping dragon) and with the progress already made on its pill formulation all that is missing right now is the finances to get it to the point where the pill is available and the myriad combo trials begin with other cancer drugs. The talk of Kevetrin being dead or being ignored by BP is pure BS and Kevetrin will be the ultimate star for cancer treatment if it then goes on to succeed in reducing tumors as Dr. Menon expects it to do.
Bottom line: Timing - Not getting caught out on a limb regarding that tricky subject but IMO we are very close to the elusive deal as IMO it is not that deals aren't being offered, but that Leo is making sure we don't give away even a single indication for Brilacidin that is not indicative of its value. As such, I think soon is within a month or two but if it stretches out a bit, so be it.
8
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....
Continue Reading
GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...
Continue Reading
Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...
Continue Reading
Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...
Continue Reading
The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...
Continue Reading
Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...
Continue Reading
The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...
Continue Reading
The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...
Continue Reading
Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...
Continue Reading
Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...
Continue Reading
Top 5 Most Recently Viewed Articles
Understanding You Call The Play Inc. (YCTP)'s Initiative In an important move for the sports betting landscape, You Call The Play Inc. (YCTP) has recently unveiled a national licensing plan and a groundbreaking measure called the Safe Bet Overlay™. This initiative is designed to foster trust and transparency within an industry that continues to grow rapidly across the...
Continue Reading
Cash for Houses Pro Achieves 5-Star Reviews Cash for Houses Pro is celebrating their recent success in receiving numerous 5-star reviews on Google for their service known as 'Sell Your House Fast In Tampa FL For Cash'. This recognition reflects the team's dedication to providing homeowners with a seamless and stress-free home selling experience. About Cash for Houses Pro...
Continue Reading
Pfizer's Revised Price Target and Market Standing Recently, CFRA, a prominent financial research firm, elevated its price target for Pfizer Inc. (NYSE:PFE) from $30.00 to $31.00 per share. This adjustment comes while maintaining a 'Hold' rating on the stock, suggesting a careful observation of its market performance. The current price target reflects a valuation based on...
Continue Reading
Equinox Gold Delivers Strong Quarterly Performance Equinox Gold Corp. EQX has seen its shares rise significantly following the release of its second-quarter financial results, which exceeded market expectations. Investors reacted favorably, driving the stock up on Thursday. Financial Highlights from the Quarter In the latest quarterly report, Equinox Gold announced...
Continue Reading
Understanding the Alexandria Real Estate Equities, Inc. Lawsuit Investors have an important opportunity arising from a lawsuit against Alexandria Real Estate Equities, Inc. (NYSE: ARE). A national shareholder rights litigation firm has initiated a class action alleging the Company has violated various securities laws. This situation has caught the attention of many...
Continue Reading